Robert “Sandy” Hodgson will apply his expertise in neuropharmacology to develop new and refine existing in vivo technologies used for the assessment of novel chemical entities and new transgenic models.
In our award-winning collaboration with AstraZeneca, large animals were socially housed during cardiovascular data collection. The data obtained showed similar sensitivity to data from single-housed animals.
Immunocompetent syngeneic mouse tumor models serve as a surrogate for human patients and allow us to study how cancer therapies perform in conjunction with a functional immune system. Flow cytometry enables validation of a functional immune system and the ability to determine various cell populations. Evaluation of these cell populations then makes it possible to characterize an immune response elicited from novel therapeutics.
Charles River is pleased to announce a new partnership with Mirimus, Inc., a leader in creating complex genetically engineered models using advanced RNAi technology. RNAi combines a powerful gene manipulation platform with a rapid timeline, providing more options for precision model creation and selection.
Charles River is proud to announce that its research model breeding and services facilities in Germany and Italy have both recently received full accreditation of their animal care and use programs from AAALAC International. Only a handful of commercial breeders in Europe have received this prestigious accreditation.
We have recently added the XtremeCT II to our musculoskeletal imaging platform. HR-pQCT provides a unique in vivo assessment of bone microarchitecture in large animals. Combined with traditional densitometry and imaging technologies, XtremeCT II represents a major translational imaging tool for drug development for musculoskeletal disorders.
Endpoints typically reserved for safety evaluation of ocular therapeutics can be used to detect otherwise unnoticeable changes in systemic toxicology studies, ensuring a relevant safety profile for the clinic.
Charles River offers several imaging capabilities to support your ocular toxicology needs. Whether you need imaging of the cornea, anterior chamber and iris, or retina and fundus, we have the equipment and expertise to meet those needs.
Over the past year, Charles River ocular experts collaborated with clients to complete an impressive 40 discovery and toxicology studies. As industry leaders, our scientists are committed to sharing this experience and keeping you informed on the latest trends and innovations in their field.
In the treatment of clinical obesity, preclinical outcomes of adiposity remain critical to advancing the right drug candidate. However, there is much more to it than the scale.